Aarti Drugs (NSE:AARTIDRUGS, BOM:524348) has restored production for a "particular product" at its T-150 unit at Tarapur in Maharashtra, India, according to a filing to the stock exchanges on Saturday.
In August, the company received 'Conditional Restart Directions' for manufacturing activity from the Maharashtra Pollution Control Board, after which the company restored the manufacturing process in compliance with the Directorate of Industrial Safety and Health (DISH) recommendations.
The company said the stoppage of manufacturing of the product has no material impact on the financials and operations of the business.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。